专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2021085518A1 血清アルブミンと成長ホルモンの融合蛋白質を含有する水性医薬組成物审中-公开
公开(公告)号：WO2021085518A1
公开(公告)日：2021-05-06
申请号：PCT/JP2020/040560
申请日：2020-10-29
申请人：ＪＣＲファーマ株式会社
发明人：岡部　真二 , 山口　裕加 , 安川　秀仁
IPC分类号： A61K38/27 , A61K9/08 , A61K47/04 , A61K47/10 , A61K47/26 , A61K47/64 , A61P5/06 , C07K14/61 , C07K14/765 , C07K19/00 , C12N15/14 , C12N15/18 , C12N15/62
摘要：【課題】血清アルブミンと成長ホルモンが連結した蛋白質を含有する水性医薬組成物が開示されている。当該水性医薬組成物は，ヒト血清アルブミンとヒト成長ホルモンとの融合蛋白質を有効成分として含有してなり，該融合蛋白質の濃度が１０～１００ｍｇ／ｍＬであり，スクロースの濃度が１０～１５０ｍｇ／ｍＬであり，非イオン性界面活性剤の濃度が０．１５～１０ｍｇ／ｍＬであり，防腐剤の濃度が０．５～１２ｍｇ／ｍＬであり，緩衝剤の濃度が１～３０ｍＭであり，ｐＨが５．０～８．０であるものである。

2. 发明申请

WO2020257243A1 THERAPEUTIC PEGYLATED GROWTH HORMONE ANTAGONISTS 审中-公开
公开(公告)号：WO2020257243A1
公开(公告)日：2020-12-24
申请号：PCT/US2020/038079
申请日：2020-06-17
申请人： MOLECULAR TECHNOLOGIES LABORATORIES LLC
发明人： BRODY, Richard, S. , ZUPANCIC, Thomas, J. , KOPCHICK, John, J. , BASU, Reetobrata
IPC分类号： A61K38/27 , A61K47/48 , A61K47/60 , C07K14/61
摘要： A growth hormone receptor antagonist, comprising human growth hormone receptor antagonist G120K, wherein one amino acid of human growth hormone receptor antagonist G120K has been mutated to cysteine or wherein two amino acids of human growth hormone receptor antagonist G120K have been mutated to cysteine, and wherein the one amino acid mutated to cysteine is T142, and wherein the two amino acids mutated to cysteine are T142 and H151; and a polyethylene glycol molecule conjugated to each substituted cysteine in the human growth hormone receptor antagonist G120K mutant. These growth hormone receptor antagonists are useful in treating diseases or conditions, such as cancer and acromegaly, that are responsive to human growth hormone receptor antagonists.

3. 发明申请

WO2020165081A1 DRY PHARMACEUTICAL FORMULATIONS OF CNP CONJUGATES 审中-公开
公开(公告)号：WO2020165081A1
公开(公告)日：2020-08-20
申请号：PCT/EP2020/053304
申请日：2020-02-10
申请人： ASCENDIS PHARMA GROWTH DISORDERS A/S
发明人： SKANDS, Anja R.H. , HERSEL, Ulrich , PINHOLT, Charlotte , HEINIG, Stefan
IPC分类号： A61K9/00 , A61K9/19 , A61K38/27 , A61K47/26 , A61K47/60 , A61K47/18 , A61K47/12
摘要： A dry pharmaceutical formulation, wherein the pharmaceutical formulation comprises a CNP conjugate, a buffering agent and a bulking agent and wherein the CNP conjugate comprises a CNP moiety that is covalently and reversibly conjugated to a polymeric moiety.

4. 发明申请

WO2019161025A1 COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS 审中-公开
公开(公告)号：WO2019161025A1
公开(公告)日：2019-08-22
申请号：PCT/US2019/017964
申请日：2019-02-14
申请人： LUMOS PHARMA, INC.
发明人： THORNER, Michael, Oliver , SMITH, Roy, G.
IPC分类号： A61K31/403 , A61K31/4439 , A61K38/27 , A61P1/16
摘要： Described herein is a rsew method for treating diseases such as no«--alcoholiC fatty liver disease and non-alcoholic steatohepatius with a growth hormone secretagogue alone or in combination with a drug selected frorn a dipeptidyl peptidase-4 antagonist a glucagon- like peptide receptor agonist, a thrazolidinedione, a sodium glucose transport protein 2 antagonist, arid metformin. Compositions relating to the same are also provided.

5. 发明申请

WO2019040406A3 METHODS OF TREATMENTS USING GROWTH HORMONE VARIANTS AND COMPOSITIONS THEREFOR 审中-公开
公开(公告)号：WO2019040406A3
公开(公告)日：2019-02-28
申请号：PCT/US2018/047183
申请日：2018-08-21
申请人： OHIO UNIVERSITY
发明人： LIST, Edward, O. , BERRYMAN, Darlene E.
IPC分类号： A61K38/27 , A61K38/22 , A61K38/16
摘要： Methods of treatments using growth hormone (GH) variants (GH-V) and compositions therefor are described. Specifically, the disclosure provides methods of treating conditions resulting from GH deficiency in a manner that does not stimulate diabetogenic activity and/or that does not stimulate prolactin activity in a subject, the method comprising: administering to a subject an effective amount of a composition comprising at least one of amino acid sequence having SEQ ID NO:3 (GH-V-20K), or variants thereof. Further disclosed are methods of enhancing the ability to reverse non-alcoholic fatty liver disease in a subject using the composition comprising at least one of amino acid sequence having SEQ ID NO:3 (GH-V-20K), or variants thereof.

6. 发明申请

WO2016109823A1 TREATMENT OF PEDIATRIC GROWTH HORMONE DEFICIENCY WITH HUMAN GROWTH HORMONE ANALOGUES 审中-公开
标题翻译：人类生长激素类似物治疗小儿生长激素缺乏症
公开(公告)号：WO2016109823A1
公开(公告)日：2016-07-07
申请号：PCT/US2015068328
申请日：2015-12-31
申请人： AMUNIX OPERATION INC
发明人： CLELAND JEFFREY L
IPC分类号： A61K38/27 , A61K38/16 , C07K14/615
CPC分类号： A61K38/27 , C07K14/61 , C07K2319/00
摘要： The present disclosure provides a pediatric growth hormone deficiency (PGHD) therapy for pediatric subjects. In some embodiments, the therapy comprises administering to the pediatric patient with PGHD a human growth hormone -XTEN (hGH-XTEN) fusion protein in therapeutically effective doses once a month, two-times a month, three-times a month, or four-times a month, wherein the treatment continues for at least about 3 months from first administration, and wherein the pediatric patient's height velocity does not decline during the treatment. In some embodiments, methods disclosed herein achieve results that are not statistically inferior compared to the height velocity achieved with daily injections of hGH alone over the same period.
摘要翻译：本公开提供用于儿科对象的小儿生长激素缺乏症（PGHD）疗法。在一些实施方案中，治疗包括向患有PGHD的儿科患者以治疗有效剂量每月一次，一个月二次，一个月三次或四个月一次给予人生长激素-XTEN（hGH-XTEN）融合蛋白，每月一次，其中治疗从首次施用开始持续至少约3个月，并且其中在治疗期间儿科患者的身高速度不下降。在一些实施方案中，本文公开的方法获得的结果与在同一时期每日单独注射hGH获得的身高相比，统计学上并不差。

7. 发明申请

WO2016079302A1 LONG-ACTING GROWTH HORMONE DOSAGE FORMS 审中-公开
标题翻译：长期生长激素剂量剂型
公开(公告)号：WO2016079302A1
公开(公告)日：2016-05-26
申请号：PCT/EP2015/077229
申请日：2015-11-20
申请人： ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S
发明人： SPROGØE, Kennett , EGESBORG, Henrik , JENSEN, Steen , KURPIERS, Thomas
IPC分类号： A61K9/08 , A61K47/48 , A61K38/27 , A61P5/02
CPC分类号： A61K38/27 , A61K9/0019 , A61K9/19 , A61K47/60 , A61M5/19
摘要： The present invention relates a pharmaceutical formulation comprising a long-acting growth hormone for use in a method of treating growth hormone deficiency, wherein the long-acting growth hormone formulation is administered to a patient in a bracketed dosage regimen, to a multitude of unit dosage forms comprising a long-acting growth hormone formulation, wherein the unit dosage forms comprise increasing amounts of growth hormone equivalents and wherein the amount of growth hormone equivalents increases by at least 10% between one unit dosage form and the next higher dosage form; their use in a method of treating growth hormone deficiency and method of treating growth hormone deficiency in a bracketed dosing regimen.
摘要翻译：本发明涉及一种药物制剂，其包含用于治疗生长激素缺乏的方法的长效生长激素，其中所述长效生长激素制剂以括号的剂量方案施用于患者至多单位剂量包括长效生长激素制剂的形式，其中所述单位剂量形式包含增加量的生长激素当量，并且其中生长激素当量的量在一个单位剂型和下一个较高剂型之间增加至少10％; 它们在治疗生长激素缺乏的方法中的用途以及在括号中的给药方案中治疗生长激素缺乏的方法。

8. 发明申请

WO2016064606A1 HALOGENATED INSULIN ANALOGUES OF ENHANCED BIOLOGICAL POTENCY 审中-公开
标题翻译：增强的生物学功能的分离胰岛素类似物
公开(公告)号：WO2016064606A1
公开(公告)日：2016-04-28
申请号：PCT/US2015/055057
申请日：2015-10-12
申请人： CASE WESTERN RESERVE UNIVERSITY
发明人： WEISS, Michael A.
IPC分类号： A61K38/28 , A61K38/27
CPC分类号： A61K33/30 , A61K38/00 , A61K38/27 , A61K38/28 , A61K2300/00 , C07K14/00 , C07K14/62
摘要： An insulin molecule comprises an Asp substitution at position B10, Glu at one or more of positions corresponding to A8, B28, and B29, and a halogenated phenylalanine at position B24. The analogue may optionally include (i) N-terminal deletion of one, two or three residues from the B chain, (ii) a mono-peptide or dipeptide C-terminal extension of the B-chain containing at least one acidic residue, and (iii) other modifications known in the art to enhance the stability of insulin. Formulations of the above analogues at successive strengths U-100 to U-1000 in soluble solutions at at least pH value in the range 7.0-8.0 in the absence or presence of zinc ions at a molar ratio of 0.00-0.10 zinc ions per insulin analogue monomer. A method of lowering the blood sugar level of a patient comprises administering a physiologically effective amount of the insulin to a patient.
摘要翻译：胰岛素分子包含位置B10处的Asp取代，对应于A8，B28和B29的一个或多个位置的Glu和位置B24的卤代苯丙氨酸。类似物可以任选地包括（i）来自B链的一个，两个或三个残基的N-末端缺失，（ii）含有至少一个酸性残基的B链的单肽或二肽C-末端延伸，以及（iii）本领域已知的其他修饰以增强胰岛素的稳定性。在不存在或存在锌离子的情况下，在0.001-10锌离子/胰岛素类似物的摩尔比下，在连续的强度U-100至U-1000的溶液中至少在7.0-8.0的pH值范围内的上述类似物的制剂单体。降低患者血糖水平的方法包括向患者施用生理有效量的胰岛素。

9. 发明申请

WO2016011281A1 FORMULATIONS OF AN ALBUMIN-hGH FUSION PROTEIN 审中-公开
标题翻译： ALBUMIN-hGH融合蛋白的制剂
公开(公告)号：WO2016011281A1
公开(公告)日：2016-01-21
申请号：PCT/US2015/040793
申请日：2015-07-16
申请人： TEVA PHARMACEUTICAL INDUSTRIES LTD. , BOCK, Jason , LIN, Yen-Huei , FENG, Ping
发明人： BOCK, Jason , LIN, Yen-Huei , FENG, Ping
IPC分类号： A61K38/00 , A61K38/27 , A61K38/38 , G01N33/74 , C07K14/61
CPC分类号： A61K38/27 , A61K9/0019 , A61K38/385 , A61K47/02 , A61K47/22 , A61K47/26 , A61K47/34 , C07K14/61 , C07K14/765 , C07K2319/31
摘要： A stable liquid pharmaceutical composition comprising an albumin-human growth hormone (hGH) fusion protein whose amino acid sequence is set forth as SEQ ID NO: 1 and a buffer, wherein the stable liquid pharmaceutical composition has a pH range of 5.5-6.5.
摘要翻译：一种稳定的液体药物组合物，其包含其氨基酸序列如SEQ ID NO：1所示的白蛋白 - 人生长激素（hGH）融合蛋白和缓冲液，其中所述稳定液体药物组合物的pH范围为5.5-6.5。

10. 发明申请

WO2015188946A1 MATRIX STABILIZED LIPOSOMES 审中-公开
标题翻译： MATRIX稳定脂质体
公开(公告)号：WO2015188946A1
公开(公告)日：2015-12-17
申请号：PCT/EP2015/001192
申请日：2015-06-12
申请人： FRICKER, Gert
发明人： PARMENTIER, Johannes , PANTZE, Silvia
IPC分类号： A61K9/127 , A61K38/27
CPC分类号： A61K9/127 , A61K9/1277 , A61K38/27 , A61K47/42
摘要： The present invention relates to a composition comprising liposomes, water, and one or more solidifier(s), wherein said solidifier(s) form(s) a solid matrix in which said liposomes are embedded, and is/are contained in the inner lumen of said liposomes. The present invention further relates to a method for the production of respective compositions.
摘要翻译：本发明涉及包含脂质体，水和一种或多种固化剂的组合物，其中所述固化剂形成固体基质，其中所述脂质体被嵌入其中，并且被包含在内腔中的所述脂质体。本发明还涉及生产各种组合物的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式